
Blog Archive
-
▼
2007
(88)
-
▼
November
(11)
- Regenetech , Preclinical Studies at Johns Hopkins ...
- Cardium, Phase 2b Excellarate Clinical Study for D...
- DexCom, FDA Approval to Calibrate Its SEVEN Contin...
- DIAMYD, A TYPE 1 DIABETES TRIAL WITH THE EXPERIMEN...
- JDRF and Lilly, Research to Identify Beta Cell Bio...
- Osiris Therapeutics, Phase II Clinical Trial Evalu...
- CV Therapeutics' Anti-Ischemic Agent Ranexa(R), Re...
- Sangamo BioSciences, ZFP Therapeutic Data From Ner...
- Sirtris, Novel Endogenous SIRT1 Activator
- Forbes Medi-Tech, Final Steps in Compound Selecti...
- Nanomix, Exclusive Glucose Detection Licensing Agr...
-
▼
November
(11)
Monday, November 12, 2007
Sangamo BioSciences, ZFP Therapeutic Data From Nerve Regeneration Program
